NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Gene Solutions

Gene Solutions

Private
SingaporeHealthcare & Life Scienceshttps://genesolutions.com/

Last Round

Series C

Nov 18, 2025

Total Funding Raised

$36M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Gene Solutions is an international biotechnology company that provides a portfolio of genetic testing solutions, including non-invasive prenatal testing (NIPT) and early cancer detection, by integrating Next-Generation Sequencing (NGS) and Artificial Intelligence.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine, Medical AI, Healthcare Analytics, Drug Discovery

Business Model

B2B2C

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Application

Keywords

genetic testingnon-invasive prenatal testingNIPTliquid biopsymulti-cancer early detectionMCEDcancer diagnosticsctDNA testingprecision oncologyAI diagnosticsNext-Generation SequencingNGSmolecular residual disease monitoringMRD monitoringreproductive healthbiomarker discoverygenomic profiling

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Gene Solutions Comps

Public and private peers based on sector, stage, and business model.

Gene Solutions comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Gene Solutions Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CNov 18, 2025
Series B ExtensionSep 20, 2023
Series BOct 5, 2021

Gene Solutions Investors

Notable investors and investment history

Gene Solutions investors
InvestorRounds
Mekong CapitalSeries B Extension, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 18, 2025

    $100M round completed.

  • Sep 20, 2023

    $21M round led by Mekong Capital.

Gene Solutions Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Gene Solutions Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Gene Solutions's valuation, stock price, and market status.

Firmographic Details

HeadquartersSingapore
Year Founded2017
Last FundingNov 18, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.